1 / 1

Pirtobrutinib(Jaypirca)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Eli Lilly and Company

Formulation:

TABLET

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Jaypirca(Pirtobrutinib) Instructions:Uses,Dosage, Side Effects

JAYPIRCA, with the generic name pirtobrutinib, is an orally administered kinase inhibitor. Its active pharmaceutical ingredient targets Bruton's tyrosine kinase (BTK), including both wild-type and C481-mutated forms. It is formulated as film-coated tablets designed for oral ingestion, functioning as a small molecule, noncovalent BTK inhibitor that modulates B-cell receptor signaling pathways crucial for B-cell proliferation and survival.

Generic name

Pirtobrutinib(Jaypirca)

English name

Pirtobrutinib

Alternative Names

Jaypirca

Drug prices

Indications

Adult patients with relapsed or refractory MCL after at least two prior systemic therapies, including a BTK inhibitor.

Adult patients with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

These indications are approved under accelerated approval based on response rate.

Therapeutic Target

Bruton’s tyrosine kinase (BTK)

Active Ingredients

Pirtobrutinib

Dosage form

TABLET

specifications

50mg * 30 tablets/bottle,100mg * 60 tablets/bottle

Description

JAYPIRCA® is an oral small-molecule kinase inhibitor that selectively targets Bruton's Tyrosine Kinase (BTK). BTK is involved in the signaling pathway of B-cells, and its inhibition helps disrupt the growth and survival of B-cell malignancies. Pirtobrutinib is designed to bind reversibly to the active site of BTK, which allows for activity in patients who have developed resistance to covalent BTK inhibitors.

Dosage and Administration

Recommended dose: 200 mg orally once daily.

May be taken with or without food. Tablets must be swallowed whole with water; not to be cut, crushed, or chewed.

Dose modifications are required for severe renal impairment (eGFR 15–29 mL/min), concomitant use with strong CYP3A inhibitors or moderate CYP3A inducers, and in case of adverse reactions.

CATEGORY NAVIGATION

RECOMMENDED ARTICLES

Side effects of Pirtobrutinib

Pirtobrutinib is a kinase inhibitor. Like most powerful drugs, the use of Pirtobrutinib is accompanied by...

Friday, July 4th, 2025, 15:01

Precautions for Pirtobrutinib

As an oral targeted drug, the standard dose of Pirtobrutinib is 200mg once daily, but special attention should...

Friday, July 4th, 2025, 14:56

How effective is the targeted drug Pirtobrutinib

Pirtobrutinib(Jaypirca) is a new type of targeted therapy drug, mainly used to treat relapsed or refractory...

Friday, July 4th, 2025, 14:53

How to use Pirtobrutinib

Pirtobrutinib is mainly used to treat relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic...

Friday, July 4th, 2025, 14:50

What are the purchase channels for Pirtobrutinib?

Pirtobrutinib is a targeted drug used to treat recurrent lymphoma. It has not yet been approved for marketing in...

Friday, July 4th, 2025, 14:45

How much is Pirtobrutinib?

Pirtobrutinib is a new type of kinase inhibitor, mainly used to treat specific types of blood system diseases....

Friday, July 4th, 2025, 14:41

Departments

Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology

Contact Medical Consultant

Global Drug Search

Clinical recruitment

overseas medical treatment

Remote consultation

Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.

Click to submit medical consultant

Mailbox:Info@Lucius.La

Welcome To Consult